ASPE MEXC RealStocks
Own real ASPE shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1

Last updated: 2026-11-18 21:39:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Aspen Neuroscience, Inc. (ASPE) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $12.04, with a market capitalization of $355.63M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11.20 to $14.90. This page covers its latest market performance, valuation, price trends and company information.
$355.63M | |
$12.00 | |
$12.92 | |
$11.75 | |
$12.00 | |
270.52K | |
379.28K | |
-- | |
$14.90 | |
$11.20 | |
-- | |
2026-06-30 |
Aspen Neuroscience, Inc. (ASPE) is trading at $12.04 in after-hours trading as of 2026-11-18 20:58:09, unchanged from the regular-session close of $12.04.
After-hours trading shows how investors are pricing ASPE after the regular session closes. The current after-hours price is near the regular-session close, indicating neutral after-hours sentiment.
Over the past seven days, Aspen Neuroscience, Inc. (ASPE) moved from $12.40 to $12.04, representing a decline of 2.94% ($0.37).
The stock traded between $11.75 and $14.42 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 242.78 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 22.6%
ASPE is currently trading at $12.04, placing it 22.6% of the way from its 52-week low of $11.20 to its 52-week high of $14.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aspen Neuroscience, Inc. (ASPE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ASPE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ASPE shares and USD.
ASPE Shares to USD
1.00 ASPE shares = 12.035 USD
Calculations are estimates based on the latest available price and are for reference only.